课题基金 / 基金详情

Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)
人类乳酸脱氢酶 A (LDHA) 抑制剂作为抗癌药物的先进开发（化学生物学联盟/NCI 实验治疗合作组织）
批准号：
10004992
负责人：
Matthew Hall
金额：
$25.03万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10004992
关键词：
Advanced DevelopmentAntineoplastic AgentsBiologyBiotechnologyCell divisionChemicalsCollaborationsDrug TargetingEnzymesExhibitsHumanInvestigational TherapiesLicensingMediationMetabolicPathway interactionsPreparationPublicationsReactionResearchTechnologyWorkanti-cancercancer cellcancer typecell growthin vitro activityin vivoinhibitor/antagonistlactate dehydrogenase Amodel developmentnoveltumor

项目摘要

项目成果

Matthew Hall的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This collaborative team - composed of groups from NCI, CBC/NExT, U Penn, Vanderbilt, UAB, UNM and NCATS - aims to build on previous research by uncovering novel inhibitors of LDHA for anticancer indications. During this period, the NCATS group, as part of the LDHA collaborative team, has worked to characterize the mechanism of action of the novel LDH inhibitors, guide in vivo efficacy model development, assess in vitro activity of novel LDH degraders, and assess in vitro activity of novel tumor concentrating LDH inhibitors. Multiple publications are under preparation and technology is under negotiation for out-licensing with a small biotech.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BRD4 Inhibitors as Potential Therapeutics for Oncology
qHTS to Identify Inhibitors of Mutant and Wildtype NSD2
qHTS to Identify Activators and Inhibitors of Wip1
qHTS to Identify Inducers of Oligodendrocyte-precursor cell (OPC) Remyelination
海外基金